Karyopharm Therapeutics Inc.
Biotechnology
See how your profile stacks up against this role.
We compared the job requirements to your profile to show where you're strong and where you fall short.
The Nurse Liaison role (KNL) is a field-based position comprised of nurses reporting to the Head of Sales. The KNL partners with their commercial team members, sales, marketing, managed markets, patient advocacy, as well as medical counterparts, and medical affairs. The KNL will be responsible for establishing strategic relationships with key customers, local and regional advocacy organizations and the oncology nursing community. This collaborative approach will serve to provide education, enhanced clinical care, and the opportunity to build strategic relationships with both key customers and Karyopharm internal customers. The KNL educates and trains clinical personnel in the delivery of therapies, patient treatment management, and related clinical topics in support of the Karyopharm field sales team.
RESPONSIBILITIES:
Candidate Profile & Requirements::
QUALIFICATIONS:
At Karyopharm, base pay is one part of a competitive total rewards package that includes comprehensive benefits (medical, dental, vision, 401(k), and more), equity and the potential to receive annual target bonuses. Actual pay is based on factors such as location, experience, skills, education, and internal equity. We maintain broad salary ranges to reflect market conditions and the specialized nature of our work. The anticipated base salary range for this position is $175K-$195K USD.
Our Value Proposition::This is a uniquely exciting time to join Karyopharm Therapeutics where we are pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. We are building upon an established commercial foundation in multiple myeloma while advancing the potential of selinexor across additional hematologic and solid tumor cancers including myelofibrosis and TP53 wild-type endometrial cancer, areas where patients continue to face significant unmet needs.
Our lead therapy, XPOVIOยฎ (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1) and is approved in the U.S. for adults with relapsed or refractory multiple myeloma, with approvals in more than 50 countries and territories outside the U.S. We are also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor.
As we prepare for our next phase of growth, we are continuing to invest in critical capabilities across the organization to support future opportunities and deepen our impact in oncology. We are looking for talented people who are motivated by meaningful work, energized by growth and momentum, and excited by the opportunity to help shape what comes next in a collaborative, fast-moving environment where individual contributions are visible and valued.
Learn more at Karyopharm Therapeutics.
After you apply, unlock the direct contact details of the people who actually make the call. A quick follow-up makes you 5x more likely to land an interview.
Marcus Rivera
Chief Revenue Officer

Harbor Health

Ardent Health Services

Cetechs

Impresiv Health

By The Bay Health

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.